| Predicate |
Object |
| contentType |
Journal Article|Comment |
| endingPage |
e712 |
| issn |
2352-3026 |
| issueIdentifier |
10 |
| pageRange |
e711-e712 |
| publicationName |
The Lancet. Haematology |
| startingPage |
e711 |
| bibliographicCitation |
de la Serna J, Baumann T. The evolving multi-agent options for chronic lymphocytic leukaemia treatment. Lancet Haematol. 2022 Oct;9(10):e711–2. doi: 10.1016/s2352-3026(22)00221-6. PMID: 35988548. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1052c4b59a467158ee5ddd38f0c1100
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b0c86bb365f579aab6a2c4fa4d918c7 |
| date |
202210 |
| identifier |
https://doi.org/10.1016/s2352-3026%2822%2900221-6
https://pubmed.ncbi.nlm.nih.gov/35988548 |
| isPartOf |
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43133
https://portal.issn.org/resource/ISSN/2352-3026 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
The evolving multi-agent options for chronic lymphocytic leukaemia treatment |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D015451Q000188 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D006801 |